Clinical Trials

Inclusion Criteria:

• Patients with a histologically or cytologically confirmed diagnosis of cancer who are being evaluated and/or treated for cancer at participating sites
• Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol

Exclusion Criteria:

• Patients with invasive fungal infections
• Patients with active and/or uncontrolled infections or who are still recovering from an infection
  • Actively febrile patients with uncertain etiology of febrile episode
  • All antibiotics should be completed at least 1 week (7 days) prior to collection
  • No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
• Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e., quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HCV or HBV without documented resolution; testing for hepatitis B or other infections for eligibility will be performed only if clinically indicated
• Tumor tissue or blood collections from patients with benign tumors including desmoid tumors, carcinoma in situ, or ongoing complete disease response (CR)
  • Tumor tissue collected from patients on treatment and demonstrating partial (PR) or stable disease (SD) response will require pathology confirmation sent to the coordinating site of viable malignancy and < 90% tumor necrosis; or
  • Documentation of clinical progression by the assessing physician
• Blood collection only:
  • Blood will not be collected from patients whose disease demonstrates ongoing partial response or who are currently on treatment with ongoing (i.e., prolonged) stable disease given the poor rate of model generation from such samples